Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 8/20 | 1.00 |
| ▸ | CA12 | O43570 | 12/20 | 0.72 |
| ▸ | CA1 | P00915 | 12/20 | 0.72 |
| ▸ | CA2 | P00918 | 12/20 | 0.72 |
| ▸ | CA4 | P22748 | 12/20 | 0.72 |
| ▸ | CA9 | Q16790 | 12/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taprenepag SCHEMBL29379291 | 1.00 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Taprenepag SCHEMBL5047978 | 0.99 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399301 | 0.93 | PTGER2 (0.87) | PTGER2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL5046815 | 0.91 | PTGER2 (0.84) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399384 | 0.91 | PTGER2 (0.84) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399393 | 0.90 | PTGER2 (0.82) | PTGER2CA12CA1CA2CA4 | |
| Taprenepag Isopropyl SCHEMBL13399045 | 0.89 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5140001 | 0.89 | PTGER2 (0.81) | PTGER2CA12CA1CA2CA4 | |
| Taprenepag Isopropyl SCHEMBL29565498 | 0.89 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5049443 | 0.88 | PTGER2 (0.79) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940144-B2 | Drug containing pyridylaminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| EP-3689349-A1 | DRUG CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | Santen Pharmaceutical Co., Ltd. (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20200188377-A1 | DRUG CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-2059507-B1 | EP2 AGONIST | PFIZER PROD INC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2059507-A2 | EP2 AGONISTS | Pfizer Products Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008015517-A2 | EP2 AGONISTS | PFIZER PRODUCTS INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188377-A1 | DRUG CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | ALDH1A2, PLPBP, PTGIS | PTGER2 151/4885CA12 2654/4885CA1 3011/4885 |
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885CA12 4207/4885CA1 4803/4885 |
| US-10940144-B2 | Drug containing pyridylaminoacetic acid compound | ALDH1A2, PLPBP, PTGIS | PTGER2 151/4885CA12 2654/4885CA1 3011/4885 |
| US-20100105905-A1 | EP2 Agonists | PTGER2, PTGER1, PTGIR | PTGER2 1/4885CA12 4207/4885CA1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.